Meropenem
Nosocomial Spontaneous Bacterial Peritonitis
University of PadovaSmall moleculePhase 2/3Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Nosocomial Spontaneous Bacterial Peritonitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lipitor Tanta University | Phase 2/3 | B |
Allopurinol Tanta University | Phase 2/3 | B |
ceftazidime University of Padova | Phase 2/3 | B |
Daptomycin University of Padova | Phase 2/3 | CCC |
Same molecule, other indications
Meropenem is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →